SYMPLICITY HTN-3: Renal Artery Denervation Shows Promise in Safely, Effectively Reducing BP Over Long-Term

In the final follow-up of the randomized SYMPLICITY HTN-3 trial presented at TCT 2022 and published in the Lancet, researchers noted significant reductions in blood pressure and no signs of late-emerging complications from renal artery denervation in patients with treatment-resistant hypertension.

EPIC-STEMI: Effects of Routine Early Treatment With PCSK9 Inhibitor in STEMI Primary PCI

Routine early initiation of a PCSK9 inhibitor added to a high-intensity statin reduced LDL-C by 22% and appeared to be both safe and feasible in patients undergoing primary PCI for acute STEMI, based on findings presented at TCT 2022 and published in EuroIntervention.

EAST-AFNET 4: Early Rhythm Control and Sinus Rhythm

The effectiveness of early rhythm control (ERC) is mediated by the presence of sinus rhythm at 12 months in patients with atrial fibrillation (AFib), based on findings from the EAST-AFNET 4 trial presented during ESC Congress 2022 in Barcelona and simultaneously published in the European Heart Journal.

NCDR Paper Explores Indications For LAAO in the US

Increased thromboembolic risk, history of a major bleed, and high fall risk were the most common procedural indications for implantation with a Watchman device, according to a paper published in Circulation: Cardiovascular Quality and Outcomes. In addition, high fall risk resulted in a "modestly increased risk" of in-hospital adverse events.